相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Minkyu Jung et al.
CANCER RESEARCH AND TREATMENT (2017)
Immunotherapy in melanoma: Recent advances and future directions
C. Franklin et al.
EJSO (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
Leila Khoja et al.
ONCOLOGY LETTERS (2016)
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
Jon Bjoern et al.
ONCOIMMUNOLOGY (2016)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Proportions of blood-borne Vδ1+and Vδ2+T-cells are associated with overall survival of melanoma patients treated with ipilimumab
Kilian Wistuba-Hamprecht et al.
EUROPEAN JOURNAL OF CANCER (2016)
Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
J. Dick et al.
IMMUNOTHERAPY (2016)
Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry
Jinhyun Cho et al.
INVESTIGATIONAL NEW DRUGS (2016)
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Jeffrey Weber et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
Janet Retseck et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
T cell Bim levels reflect responses to anti-PD-1 cancer therapy
Roxana S. Dronca et al.
JCI INSIGHT (2016)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
P. F. Ferrucci et al.
BRITISH JOURNAL OF CANCER (2015)
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Yoshinobu Koguchi et al.
CANCER RESEARCH (2015)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani et al.
CELL RESEARCH (2015)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt et al.
CLINICAL CANCER RESEARCH (2015)
Recent developments and future challenges in immune checkpoint inhibitory cancer treatment
Bas D. Koster et al.
CURRENT OPINION IN ONCOLOGY (2015)
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
S. Valpione et al.
EUROPEAN JOURNAL OF CANCER (2015)
Prognostic score for patients with advanced melanoma treated with ipilimumab
Stefan Diem et al.
EUROPEAN JOURNAL OF CANCER (2015)
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Saif S. Ahmad et al.
MELANOMA RESEARCH (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review
Douglas B. Johnson et al.
ONCOLOGIST (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
Gilli Galore-Haskel et al.
ONCOTARGET (2015)
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
Elin S. Gray et al.
ONCOTARGET (2015)
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
Luis Felipe Campesato et al.
ONCOTARGET (2015)
Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
James Larkin et al.
JAMA ONCOLOGY (2015)
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Michael A. Postow et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
Geoffrey T. Gibney et al.
CLINICAL CANCER RESEARCH (2015)
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Joanna Mangana et al.
PLOS ONE (2015)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Sander Kelderman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
Yvonne Saenger et al.
CLINICAL CANCER RESEARCH (2014)
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Lidia Robert et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma
Marliese Alexander et al.
MEDICAL JOURNAL OF AUSTRALIA (2014)
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program
Alfonso Berrocal et al.
MELANOMA RESEARCH (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Ahmad A. Tarhini et al.
PLOS ONE (2014)
Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
Jianda Yuan et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
Shigehisa Kitano et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels
Anna M. Leung et al.
FRONTIERS IN ONCOLOGY (2014)
Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
P. Queirolo et al.
CANCER INVESTIGATION (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
F. Javier Ibarrondo et al.
PLOS ONE (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
Vafa Shahabi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wenshi Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Amod A. Samaik et al.
CLINICAL CANCER RESEARCH (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2009)
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade
Willemijn B. Breunis et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma
JM Reuben et al.
CANCER (2006)
分享论文
